Search Results

Dr. Ming Zhou Featured Speaker in Solute Carrier Proteins Symposium at New York Academy of Sciences

• Source: Targeted News Service (USA), April 22, 2016 Education & Schools, 3pp

Record details

GameofGates: Solute carrier proteins as the gates managing chemical access to cells

• Source: TendersInfo - Project Notices (Mumbai, India), October 6, 2016 NEWS, 2pp

Record details

Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO; STRIKE platform to deliver siRNA and other genetic medicines to the kidney for the treatment of systemic diseases and renal diseases; ; Lead pipeline programs use megalin receptors for intracellular delivery of ligand-siRNA conjugates to specific kidney cells to target and silence genes, including solute carrier proteins

• Authors : By:Media: Kathryn Morris The Yates Network LLC 914-20

• Source: Business Wire, October 7, 2024, 3pp

Record details

DrugsUP: Solute carrier proteins and the uptake of cytotoxic approved drugs

• Source: TendersInfo - Project Notices (Mumbai, India), June 23, 2015 NEWS, 2pp

Record details

Judo Bio Presents Data Demonstrating Mechanism of Receptor-mediated Delivery of Oligonucleotides Resulting in Gene Silencing in the Kidney; Preclinical data show intracellular uptake of a ligand-siRNA conjugate in vitro using megalin, an endogenous, endocytic recycling receptor on proximal tubular cells of the kidney; ; Megalin-mediated delivery of siRNA leads to significant, durable knock-down in vivo

• Authors : By:Media: Kathryn Morris The Yates Network LLC 914-20

• Source: Business Wire, October 26, 2024, 2pp

Record details

Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney; Preclinical data shows use of megalin receptors for intracellular delivery of a ligand-siRNA conjugate to silence production of target mRNA in the kidney; ; Megalin-binding genetic medicines are specifically directed to proximal tubular epithelial cells (PTECs) in the kidney to target genes that regulate systemic diseases; ; Data supports development of megalin-STRIKERs as the first drug programs to emerge from the company's STRIKE platform for ligand-siRNA therapeutics to the kidney

• Authors : By:Media: Kathryn Morris The Yates Network LLC 914-20

• Source: Business Wire, October 7, 2024, 2pp

Record details

Journal of Cellular & Molecular Medicine Issues Research Articles in Vol. 28, Issue 9

• Source: Targeted News Service (USA), May 6, 2024 Special Gathering, 3pp

Record details

Autism, diabetes, cancer & pain in new IMI Call for proposals

• Source: ENP Newswire (UK), December 22, 2016 News, 4pp

Record details

Autism, diabetes, cancer & pain in new IMI Call for proposals

• Source: ENP Newswire (UK), December 22, 2016 News, 4pp

Record details

U.S. Patent and Trademark Office Releases IC Discovery's Patent Application for Therapeutic Conjugates with Sulfated Dendrimers for Intracellular Targeting

• Source: Global IP News (India), July 1, 2017 Pharmaceutical Patent News, 3pp

Record details